Introduction
The subject of award W81XWH-04-1-0119 entitled "A prospective randomized clinical trial of celecoxib for the control of symptomatic plexiform neurofibroma in neurofibromatosis 1" was development of a clinical trial for patients with plexiform neurofibromas and neurofibromatosis 1 (NF 1). The purpose of the project was to develop the infrastructure necessary to run a multi-center clinical trial of a novel medical therapy for patients with NF 1. To this end, a consortium of seven institutions was developed, each with expertise in treating patients with NF l or tumors of the nervous system. This work culminated in the submission of a application for a Clinical Trial Award through the Department of Defense in June, 2005 (month 6 of the grant period).
Body
The research accomplishments completed in the course of this award are described below with reference to the approved Statement of Work.
Taski: Develop research protocol, months 1-4
A detailed research protocol was developed by the team at Massachusetts General Hospital. This protocol included a description of the specific aims, analysis of patient availability and enrollment goals, determination of inclusion criteria, determination of exclusion criteria, and study procedures. Issues addressed in study procedures includes informed consent/assent, mechanism of randomization and blinding, dosing schedule for adults and children, content of all study visits, clinical assessments (study endpoints), and off-study criteria. Other issues addressed include the participation of children in a drug study, intent to benefit, risk/benefit analysis, and protection of human subjects.
Reddy), University of California at San Francisco (Dr. Kelly Nicholas), Washington University at St. Louis (Dr. Allison King), and D.C. Children's National (Dr. Tena Rosser).
A collaboration with Pfizer, Inc. was established with the company agreeing to supply study drug and placebo free of charge for the study and for one-year after completion of the study.
Task 2: Operationalize the research protocol at host institutions, months 4-6
The study protocol was submitted to the Institutional Review Board at Massachusetts General Hospital. Included in this packet were adult consent forms for the coordinating center, model adult consent forms for study sites, assent forms (age 7-11) for the coordinating center, model assent forms for study sites (age 7-11), assent forms (age 12-17) for the coordinating center, model assent forms for study sites (age 12-17), a Coordinating Center Umbrella Protocol, and a sample recruitment letter. 
Conclusions
The application for a Clinical Trial Award submitted in June, 2005, was not granted. However, the resources committed under the Clinical Trial Development Award were instrumental in developing a comprehensive plan to stage a multi-center, randomized clinical trial for patients with plexiform neurofibromas and NF 1.
